World Hepatitis Day calls for efforts to eliminate hepatitis by 2030
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
News
NGM Bio raises funds to launch clinical trial of aldafermin for PSC
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…
Certain fatty molecules may help diagnose liver disease in pregnancy
Blood levels of certain fatty molecules, called short-chain fatty acids (SCFAs), in pregnant women may help diagnose intrahepatic cholestasis of pregnancy (ICP), according to…
American Liver Foundation aiming to improve care for patients
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic dysfunction-associated steatotic liver disease (MASLD)…
Gut bacterium B. longum linked to better biliary atresia outcomes
Levels of Bifidobacterium longum (B. longum), a well-known probiotic, in the gut are significantly reduced in children with biliary atresia, a study in Taiwan…
WHO prequalifies 1st home test for hepatitis C
The World Health Organization (WHO) has prequalified the first self-test kit to detect the hepatitis C virus (HCV) in a home setting, marking…
PSC treatment bexotegrast safe, eases liver scarring in early trial
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo at reducing markers of disease…
PFIC therapy IN016 earns FDA’s rare pediatric disease designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to IN016, Innorna’s experimental therapy that aims to address the root…
Facial temperature patterns could help detect MASLD: Study
Metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, and other aging-related metabolic disorders may be detectable using computer-based analyses of…
FDA OKs clinical testing in US of hepatitis D combination treatment
The U.S. Food and Drug Administration (FDA) has approved Vir Biotechnology’s request to conduct clinical testing in the U.S. of a combination of two investigational…
Recent Posts
- Stem cell therapy may boost liver health in infants with biliary atresia
- Model predicts combo therapy may cure hepatitis C in 2 months
- New trial testing probiotic for reducing liver inflammation in PSC
- This fatty liver disease diagnosis reminded me heroes are human
- Melatonin may protect the liver from cholestasis-related injury